← boardnext 2027-06-30
PBYI
Puma Biotechnology, Inc.distress 1/10 · well-funded / low risk$7.70-2%today-10% from 52w high
Lead: Small Cell Lung Cancer ( SCLC ) · est. market ~$35B (approx, global)
Revenue
$45M
Liquidity
$102M
Runway
—
Shares 1y
+1%
Price & events
+12.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-8.3%
1W
-4.2%
1M
+4.1%
3M
+19.9%
6M
+123.2%
1Y
+107.5%
2Y
-0.6%
5Y
-25.5%
All
Overview
- Market Cap
- $391.93M
- Enterprise Value
- $355.73M
- Volume
- 22.88K
- 52 Week Range
- $3.07 – $8.58
- Total Shares
- 50.90M
- Float Shares
- 38.90M
- Short %
- 8.37%
- % Held by Insiders
- 15.49%
- % Held by Institutions
- 75.06%
- RVOL
- 0.06x
- Beta
- 1.19
Pipeline stages · 1 programs
Alisertib, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 2 | Alisertib, Endocrine therapy | Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer | — | recruiting |
| 2027-10-30 Estimated 50% readout ~2027-12-14 | Phase 2 | Alisertib | Small Cell Lung Cancer | — | recruiting |
| 2028-03-31 Estimated 50% readout ~2028-05-15 | Phase 2 | Alisertib, Paclitaxel | Small Cell Lung Cancer ( SCLC ) | — | not yet recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-02-28HC Wainwright & Co.Buy
- 2024-12-23HC Wainwright & Co.Buy
- 2024-11-20HC Wainwright & Co.Buy
- 2024-11-08HC Wainwright & Co.Buy
- 2024-08-02HC Wainwright & Co.Buy
- 2024-07-26HC Wainwright & Co.Buy
Competitors — Small Cell Lung Cancer ( SCLC )
- none identified
Recent news
- 2026-07-14Puma Stock Puma Biotechnology Inc Discount Puma Biotechnology Acquisition Outlet Online PUMA Biotechnology Form S - มูลนิธิเพื่อผู้บริโภค มพบ.
- 2026-07-09Form 4 Puma Biotechnology Inc For: 8 July By Investing.com - Investing.com Nigeria
- 2026-07-09Puma biotechnology CFO Maximo Nougues sells $77,556 in stock By Investing.com - Investing.com Nigeria
- 2026-07-09Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com - Investing.com Canada
- 2026-07-08Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan
- 2026-07-08Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan
- 2026-07-08PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan - Stock Titan
- 2026-07-06PUMA BIOTECHNOLOGY, INC. SEC Filing (Jul 6, 2026) - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.